Source: ERS Course 2019 - Masterclass in pulmonary embolism



Rating:

Share or cite this content

Citations should be made in the following way:
O. Sanchez. Treatment of high-risk PE and the role of catheter-directed therapies. ERS Course 2019 - Masterclass in pulmonary embolism

Member's Comments

No comment yet.

Related content which might interest you: Management of recurrent PE in patients on anticoagulant therapy Source: Virtual Congress 2021 – Pulmonary embolism: special situations Year: 2021 Management of anticoagulant and antiplatelet therapy in patients undergoing interventional pulmonary procedures Source: Eur Respir Rev, 26 (145) 170020; 10.1183/16000617.0020-2017 Year: 2017 Treatment of CTEPH and anticoagulation of choice Source: ERS Course 2019 - Masterclass in pulmonary embolism Year: 2019 Prospects for the prevention and treatment of venous thromboembolism Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=155 Year: 2004 Effectiveness of thrombolytic therapy in pulmonary thromboembolism Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 Advanced therapies for life-threatening PE: low-dose systemic thrombolysis, catheter-directed thrombolysis and extracorporeal membrane oxygenation (ECMO) Source: International Congress 2018 – Pulmonary embolism: what we need to know Year: 2018 Interventional treatment of pulmonary embolism: catheter-delivered local thrombolysis versus reduced-dose systemic thrombolysis Source: Virtual Congress 2021 – Pulmonary embolism: controversies in management Year: 2021 Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials Source: Eur Respir J, 51 (1) 1701775; 10.1183/13993003.01775-2017 Year: 2018 Successful use of thrombolytic therapy in the management of acute proximal pulmonary embolism without significant haemodynamic compromise Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Comparision of side effects between thrombolytic and anticoagulation therapy in patients with Pulmonary Embolism Source: Virtual Congress 2020 – Pulmonary embolism Year: 2020 Management of antithrombotic agents in patients undergoing flexible bronchoscopy Source: Eur Respir Rev, 26 (145) 170001; 10.1183/16000617.0001-2017 Year: 2017 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli Source: ERJ Open Res, 7 (1) 00554-2020; 10.1183/23120541.00554-2020 Year: 2021 Efficacy and safety of systemic and prolonged low-dose thrombolysis in thromboembolic disease Source: Eur Respir J 2002; 20: Suppl. 38, 478s Year: 2002 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach Source: Eur Respir J 2015; 45: 1142-1149 Year: 2015 Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Combination of prognostic tools for identifying high-risk normotensive patients with acute symptomatic pulmonary embolism Source: Annual Congress 2010 - Pulmonary embolism Year: 2010 Should thrombolysis and sildenafil be given in the acute management of patients with large pulmonary embolism? An assessment of the short and long-term outcomes. Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019